Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft.

Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft.

Fecha de publicación online: 01/09/2009

Abstract:

Background/Aims: Orthotopic liver transplantation (OLT) is an important therapeutic option for HBV-related endstage-
liver disease, yet it is often hampered by a scarcity of organ availability. One option to increase organ availability
is the use of virologically compromised organs from HBV-infected donors. Transplantation of anti-HBcore positive grafts
has been associated with a low risk of HBV recurrence if adequately treated with nucleoside analogs, irrespective of concomitant
HBV-specific immunoglobulin therapy. Experience using HBsAg positive grafts is, however, very limited.
Methods: Here, the analysis of the cellular and humoral HBV-specific immunity of a subject with past HBV infection
(anti-HBs and anti-HBc positive) receiving an HBsAg positive liver graft is reported.
Results: Nine months post-OLT, the patient experienced a spontaneous anti-HBs re-seroconversion allowing the discontinuation
of HBIG. The data show a concurrent increase in the cellular and humoral immunity at times of reduced viral
antigenemia, demonstrating effective immune control of HBV post-OLT.
Conclusions: These data support the use of marginal organs in this setting, providing a potential strategy to further alleviate
organ shortage.

Autores: Loggi, E., F. Bihl, J.V. Chisholm, 3rd, M. Biselli, A. Bontadini, G. Vitale, G. Ercolani, G.L. Grazi, A.D. Pinna, M. Bernardi, C. Brander, and P. Andreone.
  • Código Doi: J Hepatol 50:625-630.

Suscríbete a la newsletter

Back to Top
Irsi Caixa

Impulsado por:

Fundación 'La Caixa' Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Miembro de:

Cerca

Con la colaboración de: